Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Nov 19;174:105907. doi: 10.1016/j.phrs.2021.105907

Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]

Li Runfeng a,1, Hou Yunlong e,1, Huang Jicheng d,1, Pan Weiqi a,1, Ma Qinhai a, Shi Yongxia d, Li Chufang a,1, Zhao Jin a, Jia Zhenhua e, Jiang Haiming a, Zheng Kui d, Huang Shuxiang d, Dai Jun d, Li Xiaobo d, Hou Xiaotao c, Wang Lin c, Zhong Nanshan a, Yang Zifeng a,b,c,
PMCID: PMC8603740  PMID: 34802883

Corrigendum

The authors desire to state the following:

Shijiazhuang Yiling Pharmaceutical Co., Ltd. provided the study drug, Lianhuaqingwen capsules Lot No.B2001019, for this research. It had no role in the data acquisition, statistical analysis and writing of this article.

The corresponding author, Dr. Jia Zhenhua is the son-in-law of Wu Yiling, who is the founder of the study drug manufacturer, Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Dr. Jia Zhenhua, as the leader of Hebei Provincial Department of Science and Technology NCP Prevention and Control Emergency Scientific Research Project, played a role in “funding acquisition” as to direct this government funding for the study (Grant no. 20277708D).

Zhong Nanshan signed a “cooperation project” agreement with Shijiazhuang Yiling Pharmaceutical in 2015 to test the study drug and cooperates with it.

The other authors declare that they have no conflict of interest.

The Editor notes that the article has been additionally peer reviewed post publication and its scientific rigour and correctness confirmed.


Articles from Pharmacological Research are provided here courtesy of Elsevier

RESOURCES